Loading clinical trials...
Loading clinical trials...
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND,LONG TERM STUDY OF THE SAFETY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Conditions
Interventions
Tanezumab 2.5 mg
Tanezumab 5 mg
+1 more
Locations
100
United States
Mobile Diagnostic Center
Mobile, Alabama, United States
Seton Medical Management, Inc.
Mobile, Alabama, United States
Phoenix Rheumatology Specialists, Ltd.
Phoenix, Arizona, United States
Radiant Research, Inc
Scottsdale, Arizona, United States
Advanced Arthritis Care and Research
Scottsdale, Arizona, United States
Catalina Pointe Clinical Research, Inc
Tucson, Arizona, United States
Start Date
November 17, 2009
Primary Completion Date
December 7, 2010
Completion Date
March 1, 2011
Last Updated
May 13, 2021
NCT05986292
NCT06234631
NCT07069179
NCT07364578
NCT06488144
NCT07058623
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions